[Effects of trilobine on platelet aggregation, thromboxane A2, and prostacyclin formation in rats].
Using turbidimetry we found that trilobine inhibited ADP-induced platelet aggregation both in vitro and in vivo. Incubated with TrL 0.5, 0.75, and 1.0 mg.ml-1, platelet aggregation was inhibited by 38.2%, 68.2%, and 94.0% respectively. The inhibitory rates were 47.6% and 84.0% with TrL 20 and 40 mg.kg-1 ip respectively in vivo. The formation of platelet TXB2 was inhibited by 40% with TrL 20 mg.kg-1 ip in vivo, while the formation of carotid artery wall PGI2 was not affected. The production of TXA2-like substance was inhibited by 37%, 53%, and 78% with TrL 0.5, 1.0, and 2.0 mg.ml-1 respectively.
Tan
J Q
JQ
Department of Pharmacology, Second Military Medical University, Shanghai, China.
Chu
Z X
ZX
Shen
F M
FM
Liang
H Q
HQ
Chen
H S
HS
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis*; D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D002339:Carotid Arteries; D005260:Female; D008297:Male; D009391:Nephelometry and Turbidimetry; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013929:Thromboxane B2 / Q000096:biosynthesis*
D000470:Alkaloids; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C041179:trilobine